ACOG Committee Opinion No. 337: Noncontraceptive Uses of the Levonorgestrel Intrauterine System

article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by gemini-2.5-flash-lite, 2026-07-29

The levonorgestrel intrauterine system effectively reduces menstrual bleeding and menopausal symptoms, but requires further study for use in endometriosis, hyperplasia, or with tamoxifen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The levonorgestrel intrauterine system, approved for contraceptive use for up to 5 years, also has noncontraceptive uses. It appears to reduce menstrual bleeding significantly in women with idiopathic menorrhagia. Current studies suggest that menopausal hormone therapy regimens combining the levonorgestrel intrauterine system with estradiol are effective in reducing climacteric symptoms and in inducing amenorrhea in most women after 1 year. Further studies are required before this device can be recommended as a treatment for endometriosis-associated pelvic pain, hyperplasia, or endometrial adenocarcinoma, or as adjuvant therapy with tamoxifen.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptive Agents, Female Intrauterine Devices Levonorgestrel Menorrhagia Contraceptive Agents, Female Contraceptive Agents, Female Endometrial Neoplasms Endometrial Neoplasms Endometrium Endometrium Female Humans Hyperplasia Levonorgestrel Levonorgestrel Menorrhagia Selective Estrogen Receptor Modulators Selective Estrogen Receptor Modulators Tamoxifen Tamoxifen

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

europepmc
last seen: 2026-08-14T06:11:53.302379+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:18.313808+00:00
License: CC0 · commercial use OK